文献速递白血病

MYB活性驱动急性淋巴细胞白血病中新生增强子激活及增强子-启动子互作

MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2026-01-01

本研究探讨MYB在白血病中引导病理性增强子活性驱动致癌基因表达的机制。利用高分辨率Micro Capture-C技术,发现MYB降解后其结合位点处精确的增强子-启动子互作丢失,靶基因表达显著下调。将MybTA锚定至基因沙漠区域足以且必要地成核增强子样区域,建立最远达400 kb的远距离染色质互作,激活远端隐性元件转录,该过程依赖MYB与P300/CBP的相互作用。

要点

  • MYB降解导致其结合位点处增强子-启动子互作丢失并下调靶基因表达。
  • MybTA锚定基因沙漠足以成核增强子样区域并建立远达400 kb染色质互作。
  • MYB-P300/CBP轴是增强子驱动恶性肿瘤的可治疗脆弱靶点。

核心结论

  • MYB活性足以生成增强子,通过精确的增强子-启动子交互诱导转录。
  • MYB-P300/CBP轴是增强子驱动恶性肿瘤的可治疗脆弱性。

研究设计与样本

  • 使用高分辨率Micro Capture-C技术研究MYB在白血病中 directing 病理性增强子活性的作用。
  • 通过MYB降解及MybTA锚定基因沙漠区域实验分析增强子成核与染色质互作。

主要发现

  • MYB降解后,MYB结合位点处高度定义的增强子-启动子互作丢失,与靶基因表达显著下调相关。
  • MybTA锚定基因沙漠区域足以且必要地成核增强子样区域,建立最远达400 kb的远距离染色质互作。
  • 该互作激活远端隐性元件转录,破坏MYB与P300/CBP相互作用的点突变可减少或消除此激活。

临床怎么用

  • 提示靶向MYB-P300/CBP轴可能为增强子驱动的恶性肿瘤提供治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aberrant enhancer usage is a defining feature of oncogenic transcriptional reprogramming. Therapeutic strategies that disrupt enhancer-driven gene regulation may offer new treatment avenues. MYB is a key hematopoietic transcription factor that is frequently dysregulated in a broad range of cancers and plays a critical role in sustaining malignant cell states, including in aggressive leukemia subtypes such as KMT2A-rearranged leukemias. The molecular mechanisms by which it maintains oncogenic transcription remain incompletely understood. Here, we investigate the role of MYB in directing pathological enhancer activity to drive oncogene expression in leukemia. Using high-resolution Micro Capture-C, we show that upon MYB degradation, highly defined enhancer-promoter interactions at MYB binding sites are lost, correlating with the significant downregulation of target gene expression. When anchored to a gene desert region, the Myb transactivation domain (MybTA) is sufficient and necessary for the nucleation of an enhancer-like region. Critically, long-range chromatin interactions are established up to 400 kb away from where MybTA is anchored. This results in the activation of transcription from distal cryptic elements, which is reduced or abolished in the presence of point mutations that disrupt its interaction with the coactivators P300/CBP. All these results indicate that MYB activity alone is sufficient to generate an enhancer, inducing transcription through precise enhancer-promoter cross talk, and identify the MYB-P300/CBP axis as a therapeutically actionable vulnerability in enhancer-driven malignancies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lau IJ, Bloye G, Smith AL, et al. MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia. Blood. 2026. PMID: 41949410. doi:10.1182/blood.2025030424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。